BriaCell Therapeutics (BCT) Stock Price, News & Analysis

Company Overview

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Key Stats

• Today's Range: C$6.21 to C$7.18
• 50-Day Range: C$0.51 to C$8.82
• 52-Week Range: C$4.69 to C$74.10
• Volume: 15,237 shs
• Average Volume: 14,111 shs
• Market Capitalization: C$16.32 million
• P/E Ratio: N/A
• Dividend Yield: 13.70%
• Price Target: N/A
• Consensus Rating: N/A

BCT Stock Analysis - Frequently Asked Questions

How have BCT shares performed this year?

BriaCell Therapeutics' stock was trading at C$0.81 at the start of the year. Since then, BCT stock has increased by 681.5% and is now trading at C$6.33.
View the best growth stocks for 2025 here.

How do I buy shares of BriaCell Therapeutics?

Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:BCT
• CUSIP: N/A
• CIK: N/A
• Web: www.briacell.com
• Phone: 604-921-1810
• Fax: N/A
• Employees: 16
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-2,373,845.74
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 536.29%
• Return on Assets: -122.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$0.21 per share
• Price / Book: 30.73

Miscellaneous

• Outstanding Shares: 2,578,747
• Free Float: N/A
• Market Cap: C$16.32 million
• Optionable: Not Optionable
• Beta: 1.83